AstraZeneca continues to divest Zurampic rights

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it granted Gruenenthal Group (Aachen, Germany) exclusive rights to gout drug Zurampic lesinurad

Read the full 188 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE